APLS and BIIB Related Headlines
Go Back- Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600
- Bright Horizons Family Solutions and Remitly Global to Join S&P SmallCap 600
- Guggenheim Reiterates Buy Rating on Biogen (BIIB) following Apellis deal
- William Blair Downgrades Apellis Pharmaceuticals (APLS) to Market Perform
- Biogen to acquire Apellis for $5.6 billion in cash deal
- Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
- Biogen to acquire Apellis Pharmaceuticals for $5.6 billion or $41/sh plus CVR
APLS and BIIB Related Press Releases
Go Back- Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600
- Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
